Abstract
The breast cancer resistance protein (BCRP, ABCG2) is among the latest discovered ABC proteins to be involved in MDR phenotype and for which only few inhibitors are known. In continuing our program aimed at discovering efficient multidrug resistance modulators, we conceived and synthesized new acridones as ABCG2 inhibitors. The design of target molecules was based on earlier results dealing with ABCG2 inhibition with flavone and chromone derivatives. The human wild-type (R482) ABCG2-transfected cells were used for rational screening of inhibitory acridones. The synthesis of target compounds, the inhibitory activity against ABCG2, and structure-activity relationships are described. One of the acridones was even more potent than the reference inhibitor, GF120918, as shown by its ability to inhibit mitoxantrone efflux.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters / genetics*
-
Acridines / chemical synthesis*
-
Acridines / pharmacology*
-
Acridones / chemical synthesis*
-
Acridones / pharmacology*
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacology*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics*
-
Catalysis
-
Cell Line, Tumor
-
Cyclization
-
Drug Design
-
Drug Resistance, Neoplasm / drug effects
-
Female
-
Flow Cytometry
-
Genes, MDR / drug effects
-
Genes, MDR / genetics
-
Humans
-
Indicators and Reagents
-
Magnetic Resonance Spectroscopy
-
Mitoxantrone / metabolism
-
Mitoxantrone / pharmacology
-
Neoplasm Proteins / genetics*
-
Spectrometry, Fluorescence
-
Structure-Activity Relationship
Substances
-
9-oxo-9,10-dihydroacridine-4-carboxylic acid 3,4-dimethoxyphenethyl amide
-
ABCG2 protein, human
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters
-
Acridines
-
Acridones
-
Antineoplastic Agents
-
Indicators and Reagents
-
Neoplasm Proteins
-
Mitoxantrone